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Abrogating the suppression of glioma-inﬁltrating Tregs in the periphery and the central nervous system is essential to successful
glioma rejection. We sought to improve the immune response in glioma-bearing mice, by investigating new strategies using
the anti-CD25 immunotherapy. We found a complete long-term survival of glioma-bearing mice treated with a combination
of systemic and intracranial anti-CD25 mAb immunotherapy as compared to systemic administration of anti-CD25 mAb. In
addition, the group of mice that had been cured by the combined anti-CD25 mAb showed long-term survival without late tumor
relapse when challenged with the GL261 glioma. The antitumor immune response was investigated by analysis of antitumor
immune response (CTL). Results showed that the use of the combined injections of anti-CD25 mAb induced eﬃcient targeting of
Tregs expansion inside and outside of the brain and altered Tregs traﬃcking in the bone marrow and brain areas where antitumor
immunity was primed.
Copyright © 2009 Marie-Denise Poirier et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Glioblastoma tumors are characterized by extensive
microvascular inﬁltration and rapid proliferation. Targeting
tumor inﬁltrating lymphocytes (TIL) as well as regulatory
T cells (Tregs) can completely destroy established solid
tumors by favoring antitumor immune responses. An
active suppression by Tregs plays an important role in
the downregulation of T cell responses to foreign and
self-antigens in the peripheral immune system. However,
convincing data regarding the role of Tregs in tumors of the
central nervous system (CNS) have been accumulating only
during the last few years. Eﬀorts aimed at developing new
therapies have focused on strategies that speciﬁcally target
tumor cells while sparing normal cells. One such approach,
immunotherapy, has shown promises within the spectrum
of agents used against malignant brain tumors.
Tumor-inﬁltrating lymphocytes (TILs) have been found
and characterized in glioma and in several experimen-
tal models [1–3]. The presence of TILs indicated that
they were involved in the induction of a local immune
response but this response was not suﬃcient to control
or reject the tumor because of the suppressive eﬀect of
Tregs [4] .T r e g sa r ed e s c r i b e da sC D 4 +CD25+ T cells that
often coexpress cytotoxic T lymphocyte-associated protein 4
(CTLA-4) [5], glucocorticoid-induced tumor necrosis factor
receptor (GITR) [6], lymphocyte activation gene-3 (LAG-
3), CD28 [7], OX-40 [8], and 4-1BB [9]. Of signiﬁcance,
Tregsconstitutivelyexpresstheforkheadfamilytranscription
factor Foxp3 [10, 11]. In addition, Tregs express a series of
markers such as CD62L, CD69, neuropilin-1, and the Th2
chemokine receptor 4 (CCR4) in a relatively speciﬁc manner
[12, 13].
The constitutive expression of CD25 on the surface of
Tregs has allowed the use of anti-CD25 monoclonal anti-
bodies for depletion studies. Recently, Tregs depletion using
anti-CD25 mAb by injection intracranially has resulted in a
gain of survival of mice bearing an established glioma as well
as an enhancement of CD8+ Tc e l lf r e q u e n c y[ 1]. The anti-
CD25 mAb is directed against the Tac epitope of the CD252 Journal of Oncology
molecule, to which it binds without leading to complement
ﬁxation, antibody-mediated cellular cytotoxicity or relevant
CD25 modulation [14]. It has been reported that CD25 can
also be a potent activator of Tregs in vivo and in vitro [15].
In the present study, we showed for the ﬁrst time
that the treatment of glioma-bearing mice by systemic and
intratumoralinjectionsofanti-CD25mAbinducedcomplete
rejection of glioma in a murine model. These results
contrasted with those of a systemic anti-CD25 treatment
alone in which case the partial depletion of Tregs was not
suﬃc i e n tt oc u r ea l lo ft h et r e a t e dm i c e[ 1].
2.Materialsandmethods
2.1. Tumor Cell Line and Animals. GL261 glioma cells were
obtained from American Type Culture Collection (Manas-
sas, VA). The cells were cultured in Dulbecco’s Modiﬁed
Eagle’s Medium (DMEM) supplemented with 10% fetal
calf serum, 5mM L-glutamine, streptomycin (100μg/mL),
and penicillin (100 units/mL) at 37
◦C in a humidiﬁed
atmosphere containing 5% CO2. C57BL/6 female mice (6–
8 weeks old) were obtained from Harlan (Indianapolis, IN).
The mice were housed and maintained under pathogen-
free conditions in accordance with a protocol approved by
the Institutional Animal Care and Use Committee of the
University of Sherbrooke.
2.2. Tumor Models. Mice were anesthetized with an
intraperitoneal injection of 0.1mL of a stock solution
containing ketamine hydrochloride 25mg/mL, xylazine
2.5mg/mL, and 14.25% ethyl alcohol diluted 1 : 3 in 0.9%
NaCl. For stereotactic intracranial injections of tumor cells,
the surgical site was shaved and prepared with 70% ethyl
alcohol and Prepodyne solution. After a midline incision, a
1mm right parietal burr hole centered 2mm posterior to
the coronal suture and 2mm lateral to the sagittal suture was
made. Animals were then placed in a stereotactic frame and
1 × 105 GL261 tumor cells were injected using a 26-gauge
needle to a depth of 3mm over a period of 3 minutes.
The total volume of injected cells was 5μL. The needle was
removed, the site was irrigated with sterile 0.9% NaCl, and
the skin was sutured with 4.0 nylon.
2.3. Intracellular Cytokine Staining. Cells were stained using
anti-CD8 (clone 53-6.7), anti-CD4 (clone L3T4), and anti-
CD25 (clone 3C7) mAbs purchased from BD Bioscience
(Mississauga, ON), followed by ﬁxation. The cells were then
permeabilized (BD Cytoﬁx/Cytoperm, BD Biosciences) and
stained with anti-INF-γ, anti-IL4 (clone 11B11), and anti-
Foxp3 (clone FJK-16s) mAbs (eBioscience, San Diego, CA).
Intracellular Foxp3 was stained using the protocol suggested
by the supplier.
2.4. CTL. Splenocytes (1 × 106 cells) were washed and
stained using antimouse CD8 (clone 53-6.7), CD62L (clone
MEL-14), CD44 (clone P2A1) (BD Bioscience), and CD107a
mAbs.Thecellswerewashed,andthree-colorﬂowcytometry
analysis was performed using a FACSCalibur cytometer
(Becton Dickinson). Cells in the lymphocyte gate staining
positively for CD8α were analyzed for CD62L and CD44
expression [16], using the Flow-Jo software (Becton Dickin-
son).
2.5. Experimental Groups. There was a total of three exper-
imental groups in the case of the in vivo studies (n =
10 mice/group). One group consisted of mice injected
intracranially with GL261 alone as described above and
previouslywithoutanti-CD25treatment[1].Asecondgroup
comprised mice injected intracranially with GL261 and
treated systemically by injection of anti-CD25 mAb (0.1mL
at 100ng/μL). A third group corresponded to mice injected
intracranially with GL261 and treated by systemic (0.1mL
at 50ng/μL) and intracranial (0.1mL at 50ng/μL) injections
of anti-CD25 mAb. The injections began one week after
tumor implantation. The mice were given three injections
per week for three weeks. All experiments were performed
in triplicates (n = 3).
2.6. Statistical Analysis. Statistical comparisons of the level
of expression of diﬀerent markers used for Tregs character-
ization in the various experimental groups were performed
using the Student paired t-test. Survival was plotted using a
Kaplan-Meier survival curve and statistical signiﬁcance was
determined by the Kruskal-Wallis nonparametric analysis
of variance followed by the nonparametric analog of the
Newman-Keuls multiple comparison tests. A P-value of .05
or less was considered signiﬁcant.
3. Results
3.1. The Progression of Glioma Accompanied Bone Marrow
Tregs Expansion. We analyzed the eﬀect of the glioma on
the expansion of the populations of CD4+ and CD8+ T
cells as well as Tregs in the bone marrow of glioma-bearing
mice at three weeks after tumor implantation (three mice
per group). The FACS analysis revealed an increase in the
percentage of CD4+ (2.99 ± 0.15) and CD8+ (1.82 ± 0.13)
T cells in the bone marrow of glioma-bearing mice when
compared to untreated glioma-free mice (controls). Results
in control animals were 0.14 ± 0.06 (CD4+) and 0.15 ± 0.04
(CD8+)( P<. 002) (Figures 1(a) and 1(b)). The intracellular
expression of Foxp3 in gated CD4+ T cells from the bone
marrow of glioma-bearing mice conﬁrmed the presence of
Tregs in 20.0%± 2.33% of the cells. In contrast, there was
an absence of these cells in control mice (Figure 1(c)). Based
on these ﬁndings as well as the fact that the bone marrow
represents the immediate tumor environment of glioma,
bone marrow-residing Tregs expressed higher levels of Foxp3
(Figure 2(a)) as compared to control mice (Figure 1(c)).
3.2. The Combined Systemic and Intracranial Treatments with
Anti-CD25 mAb Cured Glioma-Bearing Mice. We tested the
eﬃciency of two anti-CD25 mAbs clones (PC61 and 7D4)Journal of Oncology 3
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Figure 1: FACS analysis of CD4+,C D 8 +, and CD4+Foxp3+ Tc e l l s
subsets in the bone marrow of glioma-bearing mice. (a), (b) The
frequency of CD4+ and CD8+ T cells was signiﬁcantly increased
(P<. 002)inthebonemarrowofglioma-bearingmiceascompared
to control (glioma-free) mice. (c) Intracellular staining of Foxp3
in gated CD4+ T cells from the bone marrow of glioma-bearing
and glioma-free mice. Data are shown as the percentage average
of positive cells and represent the mean of three independent
experiments with three mice per group (P<. 002).
to deplete Tregs in glioma-bearing mice as well as their
capacity to induce tumor rejection in these animals. Control
animals were untreated glioma-bearing mice. Results of the
combined systemic and intracranial treatments revealed that
the brain of the glioma-bearing mice showed no evidence
of tumor growth in long-term survivors, independently of
the anti-CD25 mAb tested. FACS analysis of TILs based on
intracellular Foxp3 staining showed a complete depletion of
Tregs in animals that were treated with the combined anti-
CD25 immunotherapy (Figures 2(c) and 2(d)). In the case
of mice treated by systemic injections of anti-CD25 mAbs
alone,resultsshowedsimilarpercentagevalueswhethermAb
PC61 (6.5%±0.45%) or mAb 7D4 (7.06%± 0.6%) was used
(Figures 2(a) and 2(b)), in contrast to the untreated glioma-
bearing mice (47.2% ± 3.2%) (P<. 001) (Figure 2(e)).
All the mice bearing intracranial GL261 tumors that were
treated with the combined anti-CD25 mAb immunotherapy
remained alive (100% survival) over the period of observa-
tion (150 days). In contrast, 40% of the mice that received
only the systemic injection of anti-CD25 remained alive
over the same period of time. All the untreated glioma-
bearing animals were dead 43 days following implantation
of the tumor (Figure 3). We investigated the eﬃciency of
each regimen of anti-CD25 immunotherapy (systemic and
combined) to prevent late tumor relapse. Anti-CD25-treated
surviving mice were challenged with GL261 tumor cells 95
days after the ﬁrst implantation and left untreated. All the
mice that had previously been treated by systemic anti-
CD25 administration were dead 49 days later whereas the
animals that had previously been treated by combined anti-
CD25 administration remained alive, with apparent healthy
conditions (Figure 3).
3.3. The Administration of Anti-CD25 mAb Modiﬁed the
CD4+/CD8+ T Cells Ratio in Brain and Bone Marrow. The
ratio of TIL CD4+ and CD8+ T cells in the brain as well
as bone marrow was evaluated three weeks after tumor
implantation in untreated, systemic-treated, and combined-
treated glioma-bearing mice to assess the eﬀect of Tregs
depletion on the expansion of CD8+ T cells inﬁltrating the
glioma. The TIL cell suspension was stained with anti-CD4
and anti-CD8 mAbs. FACS analysis revealed an inversion
of the CD4/CD8 ratio in untreated glioma-bearing mice,
in which case data were 3.14 ± 0.4 (CD4+)/1.80 ± 0.07
(CD8+), giving a ratio of 1.74. In the case of mice treated
with the combined anti-CD25 mAb immunotherapy, results
were 1.53 ± 0.02 (CD4+)/2.5 ± 0.05 (CD8+), giving a ratio
of 0.52. In the instance of the group of mice treated by
systemic injection of anti-CD25 mAb, the results were 2.4 ±
0.06 (CD4+)/2.4 ± 0.05 (CD8+), giving a ratio equal to one
(Figure 4(a)). Data were signiﬁcantly diﬀerent between the
three sets of data (P<. 001). In addition, the same eﬀect on
the ratios of CD4+/CD8+ T cells was observed in the bone
marrow (Figure 4(b)). The ratios were 1.64 in the case of
untreated mice (2.99 ± 0.32 (CD4+)/1.82 ± 0.1 (CD8+)),
0.72 in the instance of the combined immunotherapy (1.66
± 0.17 (CD4+)/2.3 ± 0.25 (CD8+)), and 1.06 in systemic-
treated mice (2.13 ± 0.15 (CD4+)/2.15 ± 0.35 (CD8+)).
Diﬀerences between the three sets of data were signiﬁcant
(P<. 001).4 Journal of Oncology
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Figure 2: Depletion of Tregs by anti-CD25 mAb clone PC61 or anti-CD25 mAb clone 7D4. (a) Tregs inﬁltration in untreated glioma-
bearing (control) mice. (b), (c) Tregs depletion in mice treated by systemic or combined injections of the anti-CD25 mAb PC61. (c), (e)
Tregs depletion in mice treated by systemic or combined injections of the anti-CD25 mAb 7D4. Data are presented as the percentage average
of positive cells and represent the mean of three independent experiments (P<. 001).
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Figure 3: Combined anti-CD25 immunotherapy prolongs the survival of glioma-bearing mice. Kaplan-Meier survival graph showing a
signiﬁcant increase in the median length of survival in mice (n = 10) treated with systemic and intratumoral anti-CD25 mAb (P<. 005) and
rechallenged with GL261.Journal of Oncology 5
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Figure 4: Eﬀect of anti-CD25 mAb immunotherapy on TILs of glioma-bearing mice. (a) FACS dot plot of TILs analyzed by CD4 and
CD8 double staining. (b) Distribution of CD4+ and CD8+ T cells within context of anti-CD25 glioma immunotherapy, compared between
brain and bone marrow. Data are presented as the percentage average of cells and represent the mean of three individual experiments
(P<. 001).
3.4. The Combined Immunotherapy Treatment Induced the
Generation of CD8+CD62LlowCD44high CTLs. Tregs accumu-
late inside tumors and act to maintain a local cytokine
environment that suppresses the eﬀector function of tumor-
inﬁltrating CD8+ T cells [17]. Systemic administration of
anti-CD25 mAb has previously been shown to deplete Tregs
in tumor models and autoimmune disease [18]. Here, we
employed a novel strategy which made use of two diﬀerent
routes (systemic and systemic/intracranial) of administra-
tion of anti-CD25 mAb. The phenotype of CTL CD8+ T
cells inﬁltrating the brain of glioma-bearing mice treated
with anti-CD25 was assessed by FACS analysis using the cell
surface markers CD62L and CD44. Results showed that the
CTLs were CD8+CD62LlowCD44high T cells. Furthermore,
results revealed a frequency of CTL in mice treated with the
combined anti-CD25 immunotherapy (55.7% ± 3.5%) that
washigherthanthatinsystemic(49.2%±3.1%)oruntreated
(35.3% ±2.6%) animals (P<. 001) (Figure 5(a)).
3.5. The Immune Response Targeted the Glioma: Role of
Interferon Gamma and IL-4. The expression of INF-γ
and IL-4 cytokines was examined in CTL by intracellu-
lar staining and FACS analysis. The results of CD8+ T
cells inﬁltrating the brain were compared in the cases of
untreated, systemic-treated, and combined immunotherapy-
treated glioma-bearing mice. The CTL population induced
as a result of anti-CD25 immunotherapy expressed high
levels of INF-γ and IL-4 in the group of glioma-bearing
mice that had been treated, as compared to untreated
animals (Figure 5). In the case of INF-γ, results were
37.1%± 2.1% (combined immunotherapy), 16.7% ± 1.5%
(systemic immunotherapy), and 3.12% ± 0.7% (absence
of treatment). Data for intracellular staining of IL-4 were
58.8% ± 2.8% (combined immunotherapy), 41.3% ± 2.4%
(systemic immunotherapy), and 7.14% ± 1.2% (absence
of treatment). There was a signiﬁcant diﬀerence between
the three sets of data, with reference to the absence6 Journal of Oncology
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Figure 5: Phenotype of CD8+ CTL induced by anti-CD25 combined immunotherapy. (a) Dot plots of FACS analysis of triple staining for
expression of CD8, CD44, and CD62L, after gating the CD8+ T cell population in comparison with untreated glioma-bearing mice. (b)
Cytokine intracellular staining of IL-4 and INF-γ (c) versus CD8. The mean ﬂuorescence intensity of each marker is given in each dot plot.
Values represent the mean ﬂuorescence intensity of three independent experiments ± SD.
of treatment (P<. 002) (Figures 5(b) and 5(c)). The
cytotoxic capacity of CD8+ T cells was also examined
through the expression of CD107a (lysosomal-associated
membrane protein 1), which is described as surrogate
marker for cytolytic activity. Indeed, the frequency of
CD107a positive cells was substantially higher in TILs of
combined treated mice when compared to untreated and
systemic immunotherapy-treated glioma-bearing mice (data
not shown).
4. Discussion
Abrogating the suppression of glioma-inﬁltrating Tregs in
the periphery and the central nervous system is essential
for a successful rejection of glioma. Recent studies have
shown that Tregs suppressed the activation/proliferation of
CD4+ or CD8+ T cells in an antigen-speciﬁc manner [4, 19].
We have previously reported that the inﬁltration of gliomas
by Tregs correlated with the stage of progression [20].Journal of Oncology 7
Therefore, the current experiments were designed to test
the hypothesis that Tregs exert highly immunosuppressive
eﬀects and allow rapid growth of malignant brain tumors.
In the present study, we provide evidence for the eﬃciency
of a novel and promising strategy that combines the use of
intracranialandsystemicadministrationsofanti-CD25mAb
in an experimental glioma murine model.
Data on the use of anti-CD25 mAb monoimmunother-
apy in models of glioma are accumulating. However, this
approachhasyettobeshowntoinduceeﬃcienttumorrejec-
tion and long-term survival in murine models of glioma.
Furthermore, fundamental questions remain on the most
eﬃcient way to use this treatment, reﬂecting the complexity
of the brain immune system. The rationale basis for the use
of anti-CD25 is that the mAb inhibits clonal proliferation
of autoreactive CD4+ T cells and Tregs function by blocking
the binding of IL-2 to its receptor [1, 21, 22]. The systemic
administration of anti-CD25 has been shown to prolong the
survival of glioma-bearing mice by functional inactivation
and partial depletion of glioma-inﬁltrating Tregs [1, 22].
The partial depletion of Foxp3+ Tregs in the murine glioma
model may depend on the nature of the mAb used. For
instance, treatment of mice using the anti-CD25 mAb clone
PC61hasbeenreportedtopartiallydepleteTregswhereasthe
anti-CD25 mAb clone 7D4 did not [23, 24]. In contrast, we
showed here that targeting Tregs by combined systemic and
intracranial injections of anti-CD25 mAb eradicated glioma
from the brain of glioma-bearing mice, conferred long-term
survival, and prevented relapse, whether anti-CD25 mAb
clone PC61 or 7D4 was used. These observations stressed the
importance of the strategy of immunotherapy as opposed to
the nature of the anti-CD25 mAb in the murine model of
glioma.
There are a few reports concerning the number and
function of immunosuppressive Tregs in the bone marrow.
This is particularly surprising for two reasons. First, the bone
marrow represents a major priming site for T cell responses
and second, Tregs play important roles in promoting tumor
escape from T-cell-dependent immunosurveillance [25, 26].
In this connection, we have reported that the inﬁltration of
the bone marrow of glioma-bearing mice by Tregs correlated
with the progression of tumor growth in the brain of a
murine model as well as in glioma patients [20]. Here,
we found an increase in the population of Tregs in the
bone marrow of glioma-bearing mice whereas there was
an absence of Tregs in the case of tumor-free (control)
mice and no change in the percentage of Tregs as well as
the ratio of CD4+/CD8+ in secondary lymphoid organs as
spleen, neck, and cervical lymph node (data not shown).
Our observations supported the interpretation that the bone
marrow represented the immediate tumor environment of
glioma. Based on this observation, we compared the eﬀects
of systemic and combined (systemic and intratumoral) anti-
CD25 mAb treatments on bone marrow-residing Tregs in
glioma-bearing mice. The results showed a complete deple-
tion of Tregs from the bone marrow of mice treated with the
combined anti-CD25 mAb immunotherapy in contrast to
systemic anti-CD25 immunotherapy and untreated animals.
These observations conﬁrmed that the major expansion
of Tregs from CD4+CD25− T cells occurred in the bone
marrow of glioma-bearing mice. Furthermore, our data are
in agreement with the work of Fecci et al. [22] who suggested
that an increase of Tregs in the bone marrow is the result of a
selective traﬃcking that could be in part from the thymus,
w h e r ew eh a v er e p o r t e da ni n c r e a s eo fT r e g si nu n t r e a t e d
glioma-bearing mice [27], and other secondary lymphoid
organs. The Tregs become in the bone marrow before raising
the glioma tumor in the brain of the mice. The conversion
and/or expansion of Tregs in the bone marrow of glioma-
bearing mice are not clear and require further investigations.
T r e g sc a ns u p p r e s sn o to n l yC D 4 + T cells, but also
CD8+ Tc e l l sa n dBc e l l s[ 28]. Many observations indicate
that tumors expressing costimulatory molecules are usually
rejected more eﬃciently in vivo [29]. A role of costimulatory
signals on peripheral tumors may be to enhance and/or
maintain primed T cell responses against the tumor [30, 31].
SpeciﬁcCTLsarepresentinthebrainofglioma-bearingmice
treated with anti-CD25 and they can be activated by a suit-
able immunization protocol. Fecci et al. [22]h a v er e p o r t e d
that systemic anti-CD25 mAb enhanced T cell proliferation
and INF-γ production and strengthen antigen-speciﬁc anti-
glioma CTL response. In agreement with this ﬁnding,
we observed that the antitumor eﬀects of Tregs depletion
were mediated by a T-cell-dependent antitumor immune
response.Theeﬃcienteﬀectofcombinedanti-CD25strategy
contributed to the induction of a CD8+CD62LlowCD44high
CTL response directed against GL261.
In summary, we have shown that the combined systemic
and intratumoral injection of anti-CD25 mAb resulted in
powerful antitumoral eﬀects that were revealed by tumor
rejection, complete survival, and resistance to relapse. Our
data suggest the existence of physiologic tumor-targeted
immune response in the central nervous system mediated
by Treg depletion from the bone marrow of glioma-bearing
mice. The strategy and results reported here may be used
as a basis for a more eﬀective anti-CD25 immunotherapy in
glioma patients.
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